Study finds single dose of zilebesiran safely and effectively lowers blood pressure for six months

A single injection of the experimental medication zilebesiran was safe and effective in reducing systolic blood pressure in people with mild-to-moderate high blood pressure for up to six months, as detailed in the Phase 2 of the KARDIA -1 study, reported as late-breaking science today at the American Heart Association’s Scientific Sessions 2023. The meeting, held Nov. 11–13, in Philadelphia, is a global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.